NextCode Health, a private company enabling accelerated diagnosis of genetic diseases through the use of sequence data, has raised $15 million in Series A financing from Polaris Partners and Arch Venture Partners.
The company has also secured an exclusive license for sequence-based clinical diagnostic applications using technology developed by Decode Genetics, including IT infrastructure and data analysis capabilities.
NextCode Health is a sequence-based clinical diagnostics company that offers a solution to genome interpretation and big data challenges, using technology developed over more than 16 years at Decode Genetics, a biopharmaceutical company based in Reykjavík, Iceland.